Melissa Lavasani Advocates for Psychedelic Medicines – Podcast Episode #34 | Psychedelic Invest

On Monday, Cybin released the financial results for its first quarter, ending June 30, 2023. As of June 30, 2023, the company had $9.4 million (Canadian dollars) in cash. It translates to about $6.9 in US Dollars. The press release also included the current cash position, which is $18 million as of August 14, 2023,…

RNA gene therapy startup Shape hunts for new CEO as Series C awaits

Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss is filling the post while the Seattle

October 18, 2024

Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more

April 3, 2024

FDA finalizes guidance on cybersecurity for medical devices

Dive Brief: The Food and Drug Administration has finalized guidance intended to help device developers comply with recently enacted cybersecurity obligations for premarket submissions. In

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.